TOKYO - Major Japanese firm Eisai Co. Ltd. is to hive off its gastrointestinal (GI) R&D and marketing operations in Japan into a majority owned joint company with Ajinomoto Co. Inc., in a move that appears aimed at maximizing sales of older and pipeline products and enabling both companies to reallocate resources to other areas.
Eisai, Ajinomoto Join GI Forces In Japan Growth Quest
Eisai is to spin out its gastrointestinal business in Japan into a new joint venture with Ajinomoto, creating what the firms say will be the largest specialty operation in this sector in the country.
More from Japan
More from Focus On Asia
• By
Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs
• By
Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.
• By
Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.